Merck & Co., Inc. (MRK) Receives European Approval of its Atypical Antipsychotic Medication SYCREST(R) (asenapine) for the Treatment of Manic Episodes in Bipolar I Disorder
9/2/2010 10:48:11 AM
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--MSD (MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A). announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today’s decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The Commission Decision applies to all 27 European Member States.
comments powered by